Pathology Transformation Review 2026: NHS learnings for global lab managers

The Pathology Transformation Review 2026, chaired by Lord Carter of Coles and commissioned by the Institute of Biomedical Science (IBMS), sets out a clear case for completing pathology network transformation across the NHS. It calls for stronger workforce planning, better digital infrastructure, consistent national data, and reinvestment of efficiencies into services that directly support patient care.

The IBMS has welcomed the review as an evidence-based assessment of the challenges facing pathology and the action needed to deliver sustainable, high-quality diagnostics. Readers can view the Institute's full response here: IBMS Response to Pathology Transformation Review 2026.

Why pathology is central to NHS performance

Pathology underpins more than 95% of patient pathways and processes over 2 billion tests each year, supporting decisions in cancer, infectious disease, emergency medicine, chronic disease management, screening, and elective care.

As demand rises, laboratories must deliver faster and more complex testing while supporting increasingly personalized medicine. The review warns that delays in pathology affect the wider healthcare system, from emergency departments and cancer pathways to surgical waiting lists and hospital discharge.

Performance variation remains a significant concern

The review highlights significant variation across pathology services, with many organizations still falling short of key turnaround standards.

Key findings include:

• Fewer than half of NHS trusts meet acute turnaround standards in blood sciences.
• Fewer than one in ten organizations meet histopathology turnaround targets.
• Performance variation remains substantial despite years of transformation activity.

The report argues that a standardized national dataset would enable meaningful benchmarking, reduce unwarranted variation, and help improve diagnosis and treatment timelines, particularly in cancer pathways.

Completing integration is the priority

Nearly two decades after Lord Carter's original pathology reviews, the NHS has made progress towards service integration, but implementation remains inconsistent across regions.

The central message is that the system does not need another major reorganization. Instead, it must finish the integration already underway and ensure networks have the governance, data, workforce, and funding needed to deliver consistently.

Workforce challenges threaten future progress

Workforce pressure is one of the strongest themes in the review. The IBMS notes that biomedical scientists and pathology professionals face staffing shortages, rising demand, limited training capacity, and increasingly complex workloads.

Lord Carter describes the pathology workforce as structurally fragile and warns that transformation cannot succeed unless workforce development is addressed alongside operational and technological change.

The IBMS welcomed this recognition of biomedical scientists' contribution and the emphasis on making workforce development central to future transformation programs.

Digital maturity and automation must accelerate

Digital infrastructure is another priority. While some networks have adopted modern laboratory information systems, automation, and digital workflows, progress remains uneven across the country.

The review calls for greater investment in digital pathology, automation and robotics, interoperable laboratory information systems, data standardization, quality management systems, and performance analytics.

These technologies are presented not only as efficiency tools, but as essential enablers of quality, resilience, and workforce support.

Six recommendations for the future of pathology

The review sets out six strategic priorities:

• Complete operational integration.
• Develop a nationally comparable pathology dataset.
• Strengthen workforce planning and development.
• Align digital transformation with funding reform.
• Embed accountability and governance structures.
• Reinvest gains back into pathology services.

Together, these recommendations aim to create pathology services that are more integrated, digitally enabled, workforce-focused, and able to meet future healthcare demand.

What this means for biomedical scientists and laboratory leaders

For laboratory managers, biomedical scientists, pathology network leaders, and NHS policymakers, the message is clear: pathology transformation is no longer mainly about restructuring. It is about completing existing reforms, investing in people, modernizing infrastructure, and embedding consistent national standards.

As demand grows across cancer diagnostics, genomics, precision medicine, and population health, sustained investment in pathology will be essential to the future performance of the NHS.

A global blueprint for laboratory transformation

Although the specific recommendations are aimed at UK pathology networks, the underlying message is universal: successful laboratory transformation requires an integrated approach combining workforce development, digital maturity, operational standardization, robust performance measurement, and long-term investment. Rather than pursuing transformation as a short-term cost-saving exercise, the Pathology Transformation Review 2026 presents a model in which efficiency gains are reinvested to create more resilient, patient-centered diagnostic services.

Read the full IBMS response to the Pathology Transformation Review 2026